Stroke is the second largest cause of death worldwide, the largest cause of long-term neurological disability, and the single most costly condition for the UK National Health Service and social services. The rise in the elderly population would be expected to increase the incidence of age-related illness and disability, including stroke. However, improvements in medical and surgical stroke prevention could off-set this anticipated increase in stroke.
Peter Rothwell from the Radcliffe Infirmary, Oxford, UK and colleagues assessed the changes in stroke and transient ischaemic attack rates in two studies in Oxfordshire, the Oxford Community Stroke Project (OCSP), 1981-84, and the Oxford Vascular Study (OXVASC), 2002-04.
The population aged 75 years or older increased by a third over the 20 years between the two studies. However, age-adjusted occurrence of first stroke was reduced by around 30% in the OXVASC study compared with the expected incidence based on data from the OCSP study. For major disabling or fatal stroke the reduction was 40%. This reduction was associated with increased use of blood-pressure lowering and cholesterol-lowering drugs, and associated substantial reductions in blood pressure, cholesterol, and other risk factors.
Dr. Rothwell comments: "Although we cannot prove conclusively that the major fall in stroke incidence is a direct result of the measured increase in use of preventive medication, a causal link is highly likely. There remains significant under-treatment of individuals at risk of stroke in the community and so further major reductions in stroke incidence should be possible." (Quote by e-mail, does not appear in published paper).
In an accompanying Commentary (p 1920), Valery Feigin and Stephen Vander Hoorn (University of Auckland, New Zealand) conclude ' Rothwell and colleagues' state-of-the-art study makes an important contribution to knowledge about stroke epidemiology.'
Contact: Dr. Peter M. Rothwell, Reader in Clinical Neurology, Stroke Prevention Research Unit, University Department of Clinical Neurology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE; T):44-0-1865-224237; F): 44-0-1865-228572; E): peter.rothwell@clinical-neurology.oxford.ac.uk.
Dr. Valery Feigin, Department of Medicine, University of Auckland, Private Bag 92019, 3 Ferncroft Street, Grafton, Auckland, New Zealand; T): 64-9-3737-5599 ext 84728; F): 64-9-373-1710; E): v.feigin@auckland.ac.nz.
Journal
The Lancet